ClinicalTrials.gg
Status unknownNCT04509323Updated Aug 12, 2020

Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage

A Phase 4 interventional study of Huperzine A for Injection in Neurosensory Disorder, sponsored by Jiangsu Famous Medical Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-08-12.

Sponsored by Jiangsu Famous Medical Technology Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

  1. To evaluate the effectiveness of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage;
  2. To evaluate the safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage。
Read the detailed description

A randomized, controlled, single-center, exploratory clinical research method was used. In the treatment plan, the experimental group used basic treatment + Huperzine A, and the control group only used basic treatment, with a total of 20 cases. To evaluate the effectiveness and safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage.

02

Conditions studied

  • Neurosensory Disorder

Browse trials for

03

In context

Sensation Disorders

87 studies on the registry are indexed under Sensation Disorders; 23 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 56 interventional studies indexed under Sensation Disorders.

Browse Sensation Disorders studies →

Lead sponsor

Jiangsu Famous Medical Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged from 18 to 75 years old(including 18 and 75 years old), males or females;
  2. First onset, clinical diagnosis of hypertensive intracerebral hemorrhage, and CT confirmed that the amount of hemorrhage is between 15ml-50ml, the bleeding site is the basal ganglia, the bleeding has not penetrated into the lateral ventricle, and non-surgical patients;
  3. Those with obvious neurological dysfunction after the onset, 5≤GCS≤15 or NIHSS≥6;
  4. Admission within 72 hours after the onset of the disease, and no significant enlargement of the hematoma within 24 hours after admission (hematoma enlargement ≤ 5ml);
  5. The patient/family knows and signs the form voluntarily.

Exclusion criteria

Exclusion Criteria:

  1. Cerebral hemorrhage caused by cerebral aneurysm, brain tumor, brain trauma, cerebral parasitic disease, cerebrovascular malformation, abnormal blood vessel network at the base of the brain, cerebral arteritis, blood disease, metabolic disorder and other diseases confirmed by examination;
  2. Patients with enlarged hematoma found within 24 hours after admission (the volume of enlarged hematoma> 5ml);
  3. Patients with simple , lacunar infarction, subarachnoid hemorrhage and ischemic cerebral infarction;
  4. Patients who use anticoagulant drugs for a long time;
  5. Patients with count \<100,000, >1.4 at admission and abnormal blood coagulation function;
  6. The measured value of homocysteine at admission is higher than 15μmol/L;
  7. Patients who need surgical treatment (including ventricular drainage);
  8. Patients with severe primary diseases such as cardiovascular, liver ( or AST>1.5 times the ), kidneys (BUN>1.5 times the upper limit of normal and Cr>upper limit of normal), endocrine system and hematopoietic system;
  9. Those who are allergic to protein and test drugs;
  10. People who are dependent on drugs or alcohol;
  11. Intended pregnancy or women of childbearing age with positive pregnancy test and lactating women;
  12. Participated in other clinical trials within the past 3 months;
  13. Patients considered by the investigator to be inappropriate to participate in clinical trials.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental:Huperzine A for Injection+Basic treatment

    Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days; Basic treatment:Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.

    Drug: Huperzine A for Injection

  • No intervention
    Control:Basic treatment

    Basic treatment:Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.

Interventions

  • Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days

06

What researchers measure

Primary outcomes

  1. Extension of Glasgow Outcome Scale(GOSE) Scores at 90 days of treatment

    At the 90-day follow-up of patients, the extended Glasgow Outcome Scale (GOSE) was used to assess and judge the difference in consciousness after stroke between the two groups. The scores of minimum values is 1, the maximum values is 8, whether higher scores mean a better outcome.

    Time frame: At the 90-day

Secondary outcomes

  1. Extension of Glasgow Outcome Scale(GOSE) Scores at 30 days of treatment

    At the 30-day follow-up of patients, the extended Glasgow Outcome Scale (GOSE) was used to assess and judge the difference in consciousness after stroke between the two groups. The scores of minimum values is 1, the maximum values is 8, whether higher scores mean a better outcome.

    Time frame: At the 30-day

  2. Scores of Modified Rankin Scale(mRS) at 14 days of treatment

    At 14 days of treatment, the two groups of patients were scored with scores of Modified Rankin Scale(mRS). The mRS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 5, whether higher scores mean a worse outcome.

    Time frame: At the 14-day

  3. Scores of Modified Rankin Scale(mRS) at 30 days of treatment

    At 30 days of treatment, the two groups of patients were scored with scores of Modified Rankin Scale(mRS). The mRS score of the two groups were compared whether there were statistical differences.The scores of minimum values is 0, the maximum values is 5, whether higher scores mean a worse outcome.

    Time frame: At the 30-day

  4. Scores of Modified Rankin Scale(mRS) at 90 days of treatment

    At 90 days of treatment, the two groups of patients were scored with scores of Modified Rankin Scale(mRS). The mRS score of the two groups were compared whether there were statistical differences.The scores of minimum values is 0, the maximum values is 5, whether higher scores mean a worse outcome.

    Time frame: At the 90-day

  5. Scores of National Institute of Health stroke scale(NIHSS) at 14 days of treatment

    At 14 days of treatment, the two groups of patients were scored with scores of National Institute of Health stroke scale(NIHSS). The NIHSS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 42, whether higher scores mean a worse outcome.

    Time frame: At the 14-day

  6. Scores of National Institute of Health stroke scale(NIHSS) at 30 days of treatment

    At 30 days of treatment, the two groups of patients were scored with scores of National Institute of Health stroke scale(NIHSS). The NIHSS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 42, whether higher scores mean a worse outcome.

    Time frame: At the 30-day

  7. Scores of National Institute of Health stroke scale(NIHSS) at 90 days of treatment

    At 90 days of treatment, the two groups of patients were scored with scores of National Institute of Health stroke scale(NIHSS). The NIHSS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 42, whether higher scores mean a worse outcome.

    Time frame: At the 90-day

  8. Scores of the Barthelindex of ADL at 14 days of treatment

    At 14 days of treatment, the two groups of patients were scored with scores of Barthelindex of ADL. The Barthelindex of ADL scores of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 100, whether higher scores mean a better outcome.

    Time frame: At the 14-day

  9. Scores of the Barthelindex of ADL at 30 days of treatment

    At 30 days of treatment, the two groups of patients were scored with scores of Barthelindex of ADL. The Barthelindex of ADL scores of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 100, whether higher scores mean a better outcome.

    Time frame: At the 30-day

  10. Scores of the Barthelindex of ADL at 90 days of treatment

    At 90 days of treatment, the two groups of patients were scored with scores of Barthelindex of ADL. The Barthelindex of ADL scores of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 100, whether higher scores mean a better outcome.

    Time frame: At the 90-day

  11. Complication rate

    After 90 days of treatment, compare whether the incidence of complications (including epilepsy, hydrocephalus, infarction, rebleeding, pneumonia, gastrointestinal hemorrhage) between the two groups is statistically different

    Time frame: At the 90-day

07

Study locations

1 site
  • The Fifth Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 410103, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2020; primary completion for Feb 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Aug 12, 2020
StartEst.
Aug 3, 2020
Primary completionEst.
Feb 28, 2021
CompletionEst.
May 28, 2021
Last update
Aug 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04509323
Lead sponsor
Jiangsu Famous Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 12, 2020
Start date
Aug 3, 2020 (estimated)
Primary completion
Feb 28, 2021 (estimated)
Completion
May 28, 2021 (estimated)
Last update
Aug 12, 2020

Study contacts

Fu Xudong, PhD
Contact
fxd1064@126.com
13733167393
Zhou Shaolong, PhD
Contact
13838182963@163.com
13838182963

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huperzine A

Start the discussion